Close Menu
November 18, 2019
Sponsored by
Mission Bio

Simultaneous Single-Cell DNA and Protein Sequencing in AML Samples

Genome Webinar

This webinar will outline the results of a study that performed integrative single-cell genome and cell surface protein expression profiling of adult acute myeloid leukemia (AML) cases. 

Genomic studies of AML have identified mutations with varying allele frequencies, which suggests a step-wise acquisition of mutation in leukemogenesis. Bulk sequencing can provide prognostic information, but it cannot delineate clonal architecture at the single-cell level. Additionally, the complementation of immunophenotype with corresponding mutational analysis could elucidate important dynamics in the leukemic cell population, but has yet to be assayed in parallel.

In this webinar, Linde Miles of Memorial Sloan Kettering Cancer Center will share data from the study demonstrating that simultaneous single-cell sequencing of DNA and protein can identify populations of stem/progenitor cells with distinct clonal/mutational and protein expression profiles. She will also discuss how the method identified trends in protein expression when comparing multiple samples with similar mutations. 

Attendees of this webinar will learn about:

  • New DNA+protein capability from Mission Bio for simultaneous, targeted, single-cell DNA and protein sequencing
  • A novel 6-antibody cocktail in combination with a single-cell targeted DNA custom AML panel 
  • The relationship between mutational profile and cell surface protein expression in AML samples from six clinical research samples 
Sponsored by
Oct
08
Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
14
Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

Oct
15

In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.

Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.